Magnesium Replacement: Indications, Dosing Strategies, and Monitoring

General Indications

Magnesium supplementation is indicated when documented hypomagnesemia is present (serum magnesium < 0.70–0.81 mmol/L or < 1.7 mg/dL), particularly in high‑risk settings such as ventricular arrhythmias, torsades de pointes, hypoparathyroidism, short‑bowel syndrome, and patients receiving continuous renal replacement therapy (CRRT). 1, 2, 3

Torsades de pointes – Intravenous magnesium sulfate should be administered for recurrent torsades associated with acquired QT‑interval prolongation, even if serum magnesium is within the normal range. 3
Drug‑induced QT prolongation – Restoring serum magnesium to ≥ 2.0 mmol/L improves outcomes in patients with torsades de pointes secondary to medication‑induced QT prolongation. 3
Digitalis toxicity – Intravenous magnesium is frequently used when ventricular arrhythmias occur in the context of digoxin toxicity. 3

Intracellular magnesium deficiency causes resistance to parathyroid hormone (PTH) because magnesium is a co‑factor for adenylate cyclase; correcting magnesium levels is therefore essential for effective PTH action. 1, 2, 4
When serum magnesium is low, a significant intracellular deficit is likely and should be corrected appropriately to restore calcium‑PTH homeostasis. 1, 2, 4
Paradoxically, elevated serum magnesium can suppress PTH synthesis and secretion by activating the calcium‑sensing receptor. 1, 2, 4

Step 1 – Fluid & Electrolyte Repletion: Correct water and sodium depletion (secondary hyperaldosteronism) before addressing magnesium loss. 5, 6
Step 2 – Oral Magnesium: Provide magnesium oxide 12–24 mmol per day (e.g., gelatin capsules containing 4 mmol/160 mg MgO), preferably administered at night when intestinal transit is slower. 5, 6
Step 3 – Vitamin D Analogue: If oral magnesium fails to normalize levels, add gradually increasing doses of 1‑α‑hydroxy‑cholecalciferol (0.25–9.0 mg daily) with regular serum calcium monitoring. 5, 6
Step 4 – Parenteral Magnesium: Use intravenous or sub‑cutaneous magnesium sulfate added to saline (4–12 mmol) when oral therapy is ineffective. 5, 6
Step 5 – Dietary Adjustment: Limit dietary lipids, which can impair magnesium absorption. 5, 6

Dialysis solutions that contain magnesium should be employed to prevent electrolyte disturbances during CRRT. 7
Up to 60–65 % of critically ill patients develop hypomagnesemia, with an even higher risk during CRRT, especially when regional citrate anticoagulation is used. 7
Routine intravenous magnesium supplementation is not recommended; prevention through appropriate magnesium content in CRRT fluids is the preferred strategy. 7

Newborns exposed to maternal magnesium sulfate require individualized magnesium intake to match post‑natal serum concentrations, which may be elevated during the first days of life. 8
Reference laboratory ranges for neonates are 0.7–1.5 mmol/L during the first two weeks; monitoring should adhere to these values. 8
Magnesium deficiency can precipitate hypocalcemia by impairing PTH release. 8

Clinical practice recommends maintaining serum potassium ≥ 4 mEq/L and magnesium ≥ 2 mEq/L in patients with AMI. 9
Routine prophylactic administration of magnesium in AMI does not confer a significant mortality benefit. 9

Serum magnesium alone does not reflect total body stores; erythrocyte magnesium (~2.5 mmol/L) provides a more accurate assessment of tissue magnesium status. 8
Oral magnesium salts are poorly absorbed and may exacerbate diarrhea or stoma output; formulation choice should consider gastrointestinal tolerance. 5, 6
In patients receiving CRRT and thiazide diuretics, regular monitoring of serum magnesium and potassium is essential to avoid electrolyte imbalances. 1, 2, 4